Nearly 96 million antidepressant prescription items were prescribed in England and subsequently dispensed in the community in 2025/26. The total has grown faster than the number of identified patients since 2016/17. That raises a useful question for families and journalists: what is changing in treatment, and what do these numbers tell us about recovery?
Key findings
95.5 million: antidepressant prescription items in 2025/26.
9.1 million: identified patients in the same dataset.
45.6%: growth in prescription items since 2016/17.
27.1%: growth in identified patients over the same period.
Source: NHSBSA. These figures cover NHS prescribing in England subsequently dispensed in the community. They measure activity, not depression prevalence or recovery. [1]
Prescribing grew faster than the number of patients
The growth rates differ by 18.5 percentage points. This is a comparison of two counts, not evidence that treatment intensified or became more effective. Source: NHSBSA; calculations by THE BALANCE. [1]
What the data show
NHSBSA recorded 95,528,575 antidepressant prescription items and 9,086,160 identified patients in England in 2025/26. In 2016/17, the corresponding figures were 65,590,427 items and 7,147,694 patients. Using those published totals, THE BALANCE calculates a 45.6% increase in items and a 27.1% increase in identified patients. [1]
The difference matters. One person can receive multiple prescription items over a year. An item does not reveal the dose, treatment duration, or whether the medication changed. Antidepressants can also be prescribed for conditions other than depression. The dataset measures prescribing activity, not diagnoses or recovery. [1]
| Fiscal year | Prescription items | Identified patients |
|---|---|---|
| 2016/17 | 65,590,427 | 7,147,694 |
| 2021/22 | 83,438,128 | 8,359,838 |
| 2023/24 | 89,131,582 | 8,747,095 |
| 2024/25 | 92,642,110 | 8,888,229 |
| 2025/26 | 95,528,575 | 9,086,160 |
The pattern is clear even without explaining the cause: both measures have increased, but prescribing volume has risen more quickly. A stronger clinical analysis would need to examine treatment duration, dose, switching between medications, diagnoses, age, clinical reviews and outcomes before saying why.
The increase is not only historical. Between 2024/25 and 2025/26, prescription items rose by roughly 3.1%, while identified patients rose by about 2.2%. That one-year movement is modest compared with the nine-year change, but it points in the same direction: activity is still growing faster than the number of people recorded in the dataset. The useful next question is therefore not simply how many prescriptions were issued, but what is driving the gap between treatment volume and patient count.
More prescriptions do not prove overmedication
A 96-million headline is easy to sensationalize. It can be used to imply that depression is exploding, that millions are dependent on medication, or that prescribing itself demonstrates poor care. None of those conclusions follows from this England-specific dataset.
The better question is: if more treatment is being delivered, are we getting better at measuring whether people improve?
Administrative data are excellent at counting activity. They are much weaker at answering the question most patients care about: did the treatment help? For that, researchers need symptom change, functioning, quality of life, follow-up and information about what happened when treatment was changed or stopped.
This distinction is especially relevant to private care. A family able to pay for rapid access, multiple specialists or residential treatment may have more options than the average patient. But greater access does not automatically create better outcome measurement. An expensive treatment pathway should still be able to explain what success means, when it is measured and what happens when the first intervention is insufficient.
Area deprivation is not a measure of personal wealth
NHSBSA reported 2,276,002 identified patients in the most-deprived area group and 1,575,533 in the least-deprived group. Each is one of five deprivation groups, called quintiles. These are raw patient counts, not rates adjusted for population size or age. [1]
Source: NHSBSA. These counts do not measure depression prevalence or recovery. [1]
For affluent families, the distinction is important. A neighborhood’s deprivation score does not establish an individual’s assets or income. The figures cannot show that wealthy people take fewer antidepressants or recover faster. They identify a pattern in NHS prescribing that needs more detailed investigation.
Why this matters for affluent and internationally mobile patients
For affluent families, the useful question is what happens beyond obtaining an appointment or a prescription. Having several clinicians available does not answer who coordinates the treatment plan. That is a practical care question, not a finding about wealthy patients in this dataset.
Consider someone dividing time between London, Dubai, and Zurich. One clinician prescribes, another reviews symptoms, and a third provides psychotherapy. In this illustrative situation, the family should know who maintains the treatment history and coordinates changes. The prescribing figures do not measure how often such arrangements lead to problems.
The useful questions are straightforward. What is the medication intended to treat? What improvement should we expect? When will the plan be reviewed? What other treatments are being used? Who coordinates changes? What happens if symptoms improve only partially?
NICE recommends shared decision-making and advises people considering stopping an antidepressant to talk with their prescriber. Doses are usually reduced in stages. Withdrawal symptoms and a return of depression are not interchangeable explanations for difficulties after a change. National prescribing trends are not instructions to change an individual’s treatment. [2]
What better outcome reporting would look like
If prescribing data tell us how much treatment activity occurred, outcome data should tell us what happened next. A useful reporting system would start with a defined patient group and record symptoms and functioning before treatment, during treatment and at meaningful follow-up points. It would also show how many people could be reached later, rather than reporting only the patients who responded.
For antidepressant treatment, that could mean separating several questions that are often collapsed into one. Did symptoms improve? Did the person regain functioning at work, home or in relationships? Were adverse effects manageable? Was the medication continued, changed or stopped? If treatment ended, what happened three, six or twelve months later? Those are different outcomes, and a single prescription count answers none of them.
The same standard matters when comparing private and public treatment. A private service may offer faster access, more time with clinicians or more integrated support. Those are meaningful features, but they are not themselves proof of better clinical outcomes. A fair comparison would need similar patient groups, the same outcome definitions and comparable follow-up periods.
This is also where higher-spending patients should be especially demanding. Paying more creates a reasonable expectation of clarity: what is being measured, how often it is reviewed and what evidence supports a change in plan. The strongest private-care proposition is not simply more treatment. It is better coordinated treatment with outcomes that can be explained.
What these numbers cannot tell us
This dataset cannot tell us whether antidepressants are being prescribed too often or too rarely. It cannot establish depression prevalence, medication dependence, treatment quality or recovery. It also does not provide a complete picture of private prescribing or hospital medication supply.
International comparisons require similar caution. OECD comparisons commonly use defined daily doses per population rather than raw prescription-item counts. Placing England’s item total beside another country’s consumption measure would create a false league table. [3]
The bottom line
England’s antidepressant prescribing has expanded substantially, and prescription items have grown faster than the number of identified patients. That is a real and potentially important trend.
But the media story should not stop at “96 million prescriptions.” The more useful question is whether healthcare systems and private providers are measuring what happens after treatment starts. Access is visible. Prescribing is countable. Recovery requires a different kind of evidence, and that is why it deserves scrutiny.
For journalists
Key number: 95.5 million antidepressant prescription items in England in 2025/26.
Strongest comparison: items increased 45.6% since 2016/17, versus 27.1% growth in identified patients.
Geography: England, not the whole United Kingdom.
Important caveat: prescription counts do not measure depression prevalence or recovery.
Suggested attribution: “THE BALANCE analysis of NHSBSA prescribing data.”
Methodology and sources
This analysis uses NHSBSA’s July 23, 2026 release. Fiscal year 2025/26 means April 2025 through March 2026. Changes are calculated from exact published totals and rounded to one decimal place. The table presents five selected years from the complete annual series. Counts are not adjusted for population size, age, or clinical need. No private-patient records or THE BALANCE outcome data were analyzed.
NHSBSA also cautions that improved recording of NHS numbers affects identified-patient comparisons over time. The Electronic Prescription Service increased patient identification from 2020/21 onward. Some growth in recorded patients therefore reflects better identification, rather than only an increase in the number treated. [4]
- NHSBSA. Medicines Used in Mental Health: antidepressant drugs, England 2016/17 to 2025/26. Released July 23, 2026. Tables 1, 2, and 5.
- NICE NG222. Depression in adults: treatment and management. Recommendations, including stopping antidepressant medication.
- OECD. Health at a Glance 2025. See the pharmaceutical consumption chapter for definitions and comparability.
- NHSBSA. Medicines Used in Mental Health: overview, 2016/17 to 2025/26. See time periods and patient identification.
